Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group
Lutz, M. P.
Valle, Juan W
Wagner, A. D.
AffiliationDepartment of Oncology, Geneva University Hospital, Geneva, Switzerland.
MetadataShow full item record
AbstractLast year the field of immunotherapy was finally introduced to GI oncology, with several changes in clinical practice such as advanced hepatocellular carcinoma or metastatic colorectal MSI-H. At the virtual ASCO-GI symposium 2021, several large trial results have been reported, some leading to a change of practice. Furthermore, during ASCO-GI 2021, results from early phase trials have been presented, some with potential important implications for future treatments. We provide here an overview of these important results and their integration into routine clinical practice
CitationKoessler T, Alsina M, Arnold D, Ben-Aharon I, Lutz MP, Obermannova R, et al. Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group. Br J Cancer. 2021 Aug 23.
JournalBritish Journal of Cancer
- Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
- Authors: Bilgin B, Sendur MA, Bülent Akıncı M, Şener Dede D, Yalçın B
- Issue date: 2017 Apr
- 2016 ASCO Gastrointestinal Cancers Symposium.
- Authors: Landman A
- Issue date: 2016 Mar
- The first-line treatment for advanced pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
- Authors: Merl MY, Li J, Saif MW
- Issue date: 2010 Mar 5
- [ASCO 2006 Gastrointestinal Cancers Symposium, San Francisco, 26-28 January 2006].
- Issue date: 2006 Mar-Apr
- Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists.
- Authors: Stein A, Moehler M, Trojan J, Goekkurt E, Vogel A
- Issue date: 2018 Oct